Opinion|Videos|January 17, 2025
ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas
Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the potential for combination therapies to be more viable in certain B-cell lymphoma subtypes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With several abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 studying bispecific therapies in combination with conventional chemotherapy regimens, what factors should clinicians consider when deciding between monotherapy and combination approaches for bispecifics in FL and DLBCL?
- Do you see combination therapies with bispecifics as more viable in certain subtypes of B-cell lymphoma compared with others? Why or why not?
Advertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5